Antagonists of the substance P (SP) preferring neurokinin 1 receptor (NK 1 -R) represent a promising novel class of drugs for the treatment of stress-related disorders including depression and anxiety disorders. The underlying neuronal mechanisms involved in the effects of these drugs, however, are poorly understood. By using in vivo microdialysis we observed increased SP, but reduced serotonin (5-HT) release during forced swim stress (FST) in the rat lateral septum (LS), a key area in processing emotions and stress responses. Acute administration of the selective high affinity NK 1 -R antagonist L-822429 injected either systemically or locally into the LS reversed the FST-induced decrease in 5-HT efflux and facilitated active coping strategies during the FST. Increased active coping in the FST was attenuated by intraseptal 5-HT 1A -R blockade with WAY100635, indicating that the behavioural effect during NK 1 -R blockade is mediated by enhanced intraseptal serotonergic transmission acting on 5-HT 1A -R. Taken together, our findings identify the LS as an important brain area for the modulation of stress responses by the SP/NK 1 -R system. NK 1 -R blockade resulted in behaviorally significant enhancement of 5-HT transmission. We show for the first time that this modulation does not necessarily involve interaction with neuronal firing at the cell body level of 5-HT neurons as previously postulated, but can be elicited in a terminal region of these neurons.
Increasing evidence suggests that substance P (SP) and its receptor, namely the neurokinin 1 receptor (NK 1 -R), play an important role in the modulation of stress-related, affective and/or anxious behaviours. Both SP and NK 1 -R are expressed in brain regions critically involved in stress, fear and affective responses such as the amygdala, hippocampus and frontal cortex. In this study we aimed at identifying the types of NK 1 -R immunoreactive neurones in the basolateral complex of the amygdala according to their content of other neurochemical markers by dual or triple labelling immunofluorescence. The basolateral amygdaloid complex consists of the lateral (LA) and basolateral (BL) nuclei, which are believed to be cytoarchitectonically similar. Our study reveals that in the rat LA, 38.7 ± 6.7% of NK 1 -R immunopositive interneurones (124 ⁄ 331) co-express the calcium binding protein parvalbumin (PV), representing 15.2 ± 3.4% (124 ⁄ 820) of PV + neurones. Conversely, in the BL no coexistence between NK 1 -R (293 neurones counted) and parvalbumin (2385 neurones counted) expressing interneurones was detected. These results suggest that interneurones in the LA and BL differentially express molecules involved in cell signalling and indicate a distinct organization in local interneurones. The BL resemble the hippocampal region CA1, in which NK 1 -R-expressing neurones do not coexist with PV [1] . References 1. Acsády L, Katona I, Gulyás AI, Shigemoto R and Freund TF. Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J Comp Neurol 1997, 378:320-336.
Adenosine receptors are G protein-coupled receptors and are implicated in several neurological and psychiatric disorders such as Parkinson's disease, schizophrenia and Alzheimer's disease. These receptors can be distinguished by their affinity for adenosine analogues and by their preferred signal transduction pathway. The A 2A receptor has an unusually long intracellular carboxyl terminus. We identified SAP102 (synapse-associated protein of 102 kDa) as a novel interaction partner of the adenosine A 2A receptor. SAP102 belongs to the family of MAGUK (membraneassociated guanylate kinase-like domain) proteins. These proteins have an established function in synaptic organization, which is reflected by their modular structure. Our data demonstrate that the A 2A receptor binds to C-terminal domains of SAP102. Furthermore we identified the responsible binding motif consisting of 5 amino acids in the receptor's C-terminus. In hippocampal neurons we observed a co-localization of both proteins especialy in punctuate structures along the neurite extensions that presumably represented dendritic spines. In the next step we will use several fluorescence-based techniques in order to investigate the influence of SAP102 on the mobility and targeting of the A 2A receptor.
The cardiac isoform of the Na + channel (Na V 1.5) is known to accumulate in the endoplasmic reticulum (ER). This retention presumably reflects quality control in the ER. In order to understand the underlying mechanism, we heterologously expressed the human orthologue of the Na + channel (Na V 1.5) in neonatal primary rat and murine cardiomyocytes, in a cardiomyoblast cell line (H9c2) and in HEK293 cells (internal control). In HEK293 cells, Na V 1.5 readily accumulated at the cell surface and gave rise to functional channels with the expected electrophysiological properties. In contrast, in cardiomyocytes and H9c2 cells, the Na V 1.5 accumulated in the ER regardless of the transfection method employed (lipofection, nucleofection).
As a positive control, we employed G protein-coupled β 1 -adrenergic, A 1 and A 2A adenosine receptors. In HEK293 cells, export of the A 2A receptor is known to be enhanced by the deubiquinating enzyme USP4. Accordingly, we also coexpressed USP4 and the A 2A receptor in the different cardiomyocyte preparations. However, in all instances, the membrane proteins were trapped within intracellular compartments. This was, in particular true for the Na V 1.5, which, in many instances, accumulated in circular bodies, which are reminiscent of calnexin-rich organized smooth ER structures. Based on these findings, we conclude that (i) membrane proteins undergo stringent quality control in cardiac myocytes and (ii) ER-export of the Na V 1.5 is limited by the availability of additional cardiomyocyte-specific components.
The PI3Kδ isoform is a candidate drug target in leukemia. Here, we explored its role in Abelson-induced leukemia. Selective serotonin reuptake inhibitors (SSRIs) have recently been reported to specifically kill malignant cells of B-lymphoid origin. However, we found that all cell lines investigated underwent apoptotic cell death when exposed to SSRI concentrations exceeding 10 µM, regardless of whether the cell lines were derived from B-or T-lymphoid tumors or other sources. The structure-activity relationship readily distinguished the pro-apoptotic and growth-inhibitory effect of SSRIs from their eponymous action: acetylation of the SSRIs fluvoxamine and paroxetine abrogated the ability of these compounds to inhibit 5-HT uptake, but did not impair their cytotoxic action. Based on these data we conclude that (i) SSRIs inhibit growth of transformed cells, but that (ii) this effect is neither specific for malignant cells nor specific for any particular cellular subset. (iii) The proapoptotic effect of SSRIs (at µM concentrations) is unrelated to their principal pharmacological action, i.e. inhibition of serotonin uptake (at nM concentrations). SSRIs or improved versions thereof are therefore unlikely to represent useful lead compounds for inducing apoptosis in B-cell derived tumors. Anticonvulsant actions of dynorphin were proposed since more than 2 decades, however till now, we do not have information on the functions of endogenous dynorphin. Thus, we investigated prodynorphin knockout (KO) mice in different models of seizures and epilepsy. Seizure threshold was investigated by tail-vein infusion of 100 µg pentylenetetrazole (PTZ)/ml at a rate of 100 µl/min until mice displayed generalized clonic seizures. Wild-type mice showed clonic seizures at 39.2 ± 1.88 (mean ± SEM; n = 5) mg PTZ/kg body weight. KOs displayed a significantly reduced seizure threshold of 32.7 ± 1.17 (n = 6) mg PTZ/kg. This phenotype could be rescued entirely by the κ opioid receptor specific agonist U-50488, but not the µ opioid receptor specific agonist DAMGO. The δ opioid receptor specific agonist SNC80 decreased seizure threshold in both genotypes. Pre-treatment with the κ-selective antagonist GNTI completely blocked the rescue effect of U-50488. After injection of kainic acid into stratum radiatum of CA1 of the dorsal hippocampus, KO mice displayed increased neuronal loss along the rostro-caudal axis of the ipsi-and partially the contralateral hippocampus at early time points after treatment. Thus, marked neurodegeneration was seen already 1 week after treatment in KO mice. investigated the causal factors and mechanism of sensitization in SH-SY5Y cells. The degree of sensitization depended on pre-incubation of the cells with retinoic acid; however, maximizing the extent of sensitization required the withdrawal of serum from the culture medium. This was necessary for the cells to secrete endogenous substances into the culture supernatant. Because sensitization was blocked by inhibitors of gene transcription we surmised that the autocrine factors were relevant for sensitization and were generated by de novo protein synthesis. A gene expression screen revealed several factor candidates (including dkk1, EphB2, NPY, VEGFB); our preliminary data indicated that a combination of these may be needed to induce full sensitization. Our data further suggest that sensitization was not due to up-regulation of stimulatory G proteins or adenylyl cyclase. Rather, the immediate cause may be clustering of the catalyst and its activator G s . This interpretation is consistent with the effect caused by altering the membrane lipid composition which enhanced and reduced cAMP formation in undifferentiated and differentiated cells, respectively. Among the four receptors for the purine nucleoside adenosine the A 2A receptor subtype is the only one with an extended cytoplasmic domain and this is due to a remarkably long carboxyl terminal tail (C-tail). We have previously identified from an adult human brain cDNA library potential interaction partners which bind to the receptor C-tail and suggest that they impinge on receptor biology. (i) ARNO, the activator of the small GTP-binding protein ARF6, was shown to propagate sustained receptor signalling to ERK (extracellular signal regulated kinase); (ii) the ubiquitin-splitting protease USP4 controls receptor turnover; (iii) SAP (synapse-associated protein) 102 may form an anchor localizing the receptor in nerve cells. While ARNO binds to the membrane proximal portion, USP4 and SAP102 recognize more distal segments of the C-tail. In the case of SAP102 the recognition sequence could be narrowed down to a stretch of five amino acid residues (DVELL) which is conserved between species. A receptor where the DVELL sequence was changed to RVRAA has been characterized upon stable transfection of HEK293 cells (which express SAP102). Surface expression, radioligand binding and receptor-dependent stimulation of the effector adenylyl cyclase were similar to the wild type. In contrast, the agonist-dependent activation of ERK was attenuated in cells stably expressing the mutant receptor. Hence, SAP102 may be necessary to establish a signalling complex including ERK and the receptor as has been previously observed for the NMDA receptor in nerve cells. Perfluorooctanoic acid (PFOA) has anti-inflammatory effects in models of cutaneous inflammation, possibly via activation of PPAR-α and PPAR-γ. We have therefore investigated whether PFOA has similar effects in a model of acute oedematous pancreatitis and whether such effects could be explained by agonism at PPAR-α or PPAR-γ. Acute pancreatitis was induced in anesthetized rats by i.v. infusion of the cholecystokinin analogue, caerulein. The PPAR-α agonist clofibrate or the PPAR-γ agonist rosiglitazone were injected s.c. before the experiments. Pancreatic oedema, neutrophil activation and production of prostaglandin (PG) E 2 and prostacyclin (via 6-keto-PGF 1α ) were assessed in the pancreas. Acute pancreatitis caused significant oedema formation, neutrophil activation as assessed by myeloperoxidase activity in the tissue, and increased synthesis of pro-inflammatory prostanoids. Neutrophil activation was unaffected by clofibrate but was abolished by rosiglitazone. In contrast, prostanoid synthesis was unaffected by rosiglitazone but was inhibited by clofibrate. In conclusion, our data demonstrate that activation of PPAR-α and PPAR-γ has differential anti-inflammatory effects in acute interstitial-oedematous pancreatitis. Neutrophil activation is sensitive to inhibition by PPAR-γ activation while the production of pro-inflammatory prostanoids can be attenuated by activation of PPAR-α. Thus, the antiinflammatory potential of PPAR-α and PPAR-γ ligands should be further investigated. Introduction: Tariquidar (TQD, Xenova, UK) is a thirdgeneration inhibitor of the multidrug efflux transporter P-glycoprotein (P-gp) with potential applications in neurology and oncology in order to increase drug exposure of tissues targeted for treatment. We used small-animal positron emission tomography (µPET) with the P-gp substrate (R)-[ 11 C]verapamil (VPM) in order to measure in vivo the degree of P-gp inhibition at the rat blood-brain barrier (BBB) after administration of different doses of TQD. Methods: Wistar Unilever rats received intravenous doses of 0, 1, 3, 5, 7.5 and 15 mg/kg of TQD followed by a 1-hour VPM µPET scan recorded at 2 hours after TQD administration. Brain-to-plasma radioactivity ratios were fitted to a sigmoidal dose-response curve.
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Results: TQD inhibited P-gp-mediated efflux of VPM across the BBB with an apparent half-maximum effective dose (ED 50 ) of 6.6 mg/kg (95% confidence interval: 4.9-8.2 mg/kg) which was in good agreement with previous data reported in mice for another P-gp substrate (loperamide, ED 50 : 5.7 mg/kg) [1] . Brain-to-plasma radioactivity ratios after 0 and 15 mg/kg of TQD were 0.23 and 3.15, respectively. Conclusion: Our data suggest that TQD is a potent inhibitor of P-gp at the rat BBB. Moreover, VPM PET appears to be a useful tool for in vivo dose finding of novel P-gp inhibitors in animals and humans. tracer to measure P-glycoprotein (P-gp)-mediated transport at the blood-brain barrier (BBB). Owing to the lack of a suitable reference region in brain that is devoid of P-gp, a metabolite-corrected arterial input function is required for quantitative analysis of VPM PET data [1] . The aim of this study was to compare metabolism of VPM in epilepsy patients and healthy volunteers. Methods: Selected arterial blood samples from 9 patients, who underwent VPM PET, were analyzed for radiolabeled metabolites by a previously described combined solid-phase extraction/HPLC assay [2] . Results: VPM metabolism was significantly faster in patients as compared to healthy volunteers [1] (unchanged VPM at 60 min after injection: 26.1 ± 6.4 vs. 49.0 ± 13.4%, p < 0.05, t-test). Conclusion: Faster metabolism of VPM in epilepsy patients may be caused by CyP450 enzyme induction by antiepileptic drugs. Based on these data caution is warranted when using an averaged arterial input function derived from healthy volunteers for the analysis of patient data. As radiolabeled metabolites of VPM are known to cross the BBB [1] , different kinetic modeling parameters obtained in patients and healthy volunteers might be at least partly attributed to different rates of tracer metabolism rather than to differences in cerebral P-gp activity. Introduction: Inhibition of the multidrug efflux transporter P-glycoprotein (P-gp) at the blood-brain barrier (BBB) is considered a promising strategy in order to increase intracerebral penetration of therapeutics, such as antiepileptic and anticancer drugs. The aim of this study was to evaluate the usefulness of (R)-[ 11 C]verapamil (VPM) and small-animal positron emission tomography (µPET) to measure P-gp inhibition at the BBB following administration of the third-generation P-gp inhibitor tariquidar (TQD, Xenova, UK). Methods: Five Wistar Unilever rats underwent paired VPM µPET scans, one baseline scan followed by i.v. administration of TQD (15 mg/kg) and a second PET scan at 2 hour after TQD administration. Arterial blood sampling was performed along with analysis of metabolism and plasma protein binding of VPM.
Results: Following TQD administration, the brain-to-plasma ratio of radioactivity was increased by a factor of 11-16 as compared to baseline scans, whereas VPM metabolism and plasma protein binding were left unaffected. Conclusion: Our pilot data suggest that VPM PET is a sensitive tool to quantitatively visualize P-gp inhibition at the animal and human BBB. Inhibition of mTOR complex 1 (mTORC1) with rapamycin leads to phosphorylation of AKT in some cancer cells with unknown biological consequences. A mechanism involving insulin receptor substrate (IRS) and phosphatidylinositol 3-kinase (PI3K) leading to increased AKT phosphorylation has been described. For melanoma, it is unknown, whether this feedback loop plays a role, although preliminary clinical data indicate poor activity of rapalogues in melanoma. Here, we report that treatment of melanoma cells with rapamycin resulted in strong and long lasting AKT phosphorylation, but had little or no effects on cell viability, cell cycle arrest or apoptosis. Combined PI3K/mTOR inhibition with LY294002 had strong effects on these parameters, but also led to increased phospho-AKT levels after prolonged treatment. In contrast to the single treatments, combination of rapamycin plus LY294002 was able to suppress AKT phosphorylation even after prolonged treatment. Inhibition of mTOR complex 2 (mTORC2) using RNAi led to reduced levels of p-AKT, also under conditions when mTORC1 was inhibited. PTEN mutant melanoma cells showed slightly increased levels of AKT phosphorylation compared to PTEN wild-type cells. Thus, our results indicate that mTORC1 inhibition with specific inhibitors such as rapamycin as well as with multitarget inhibitors such as LY294002 can lead to AKT phosphorylation in melanoma cells via mTORC2, but without significant influence on treatment efficacy in vitro.
weeks we determined the closure time (CT) of collagen/epinephrine cartridges obtained by the PFA-100 (CEP-CT), and the surface coverage (SC), as a measure of platelet adhesion, with and without pre-incubation with arachidonic acid (ARA). By the PFA-100 CEP-CT was median 210 ± 62 before aspirin, and >300 sec in all individuals taking aspirin for 2 weeks (p < 0.0001). The SC pre-incubated with ARA was median 4.6 ± 2.5 before study entry and median 6.8 ± 2.7 after two weeks of aspirin (p < 0.0001). Changes were not significant in controls. In order to normalize for the broad variation of the SC from one individual to the next, we determined the relative change of the SC due to the addition of ARA. Again, aspirin significantly inhibited ARA induced reduction of adhesion (p = 0.014). Sensitivity and specificity to detect aspirin was 100% and 50% with the PFA-100, 100% and 42% with the Impact-R.
Conclusion:
The PFA-100 (collagen/epinephrine) and the Impact-R are useful to estimate the individual response to aspirin. While a variety of factors may contribute to prolonged CEP-CT by the PFA-100, the Impact-R ARA test is specific for aspirin. 
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The basic difference in the pharmacological spectrum between methamphetamine and its derivative, the enhancer substance (−)-deprenyl Ildikó Miklya
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary E-Mail: mikild@hotmail.com
Beta-phenylethylamine (PEA), the parent compound of both methamphetamine and (−)-deprenyl, has two effects: it is a releaser of catecholamines and a natural enhancer substance. Methamphetamine, the closest mother compound of (−)-deprenyl, acts like PEA. (−)-Deprenyl was the first PEA derivative which lost the releasing property but preserved the enhancer effect. We elaborated a method on isolated rat brain stem which allowed to measure the enhancer effect of (−)-deprenyl and to detect how the releasing effect of methamphetamine hinders the recognition of its enhancer effect. We fill up the intraneuronal transmitter stores of the noradrenergic neurons in an isolated rat brain stem with It has been proposed that P2X 3 receptors possess a unique mechanism of agonist-induced conformational transitions.
Recovery from ATP-induced desensitization was found to be very slow; during this period a special agonist binding site was supposed to be formed which should bind the agonist with high affinity and promote desensitization without activation. The authors supposed that this high affinity binding site is absent from non-activated receptors. The theory was supported by an unexpected outcome of an experiment in which a low concentration of agonist was applied at different phases during recovery from desensitization. The inhibition by a low concentration of agonist was stronger when it was applied during the early phase of recovery when more desensitized receptors were present. The authors used different agonists for initial desensitization and for prolonged perfusion at low concentration. We repeated the experiment on HEK 293 cells expressing human P2X 3 receptors with the same results. However, when we used the same agonist at both concentrations the inhibition was stronger when the low concentration was applied during the late phase.
Simulations revealed that formation of high affinity binding sites does not require any unique mechanism and can be readily described by an allosteric mechanism. Furthermore, they predict that the unexpected phenomenon can only occur when a rapidly dissociating drug is replaced by a slowly dissociating drug on the receptor.
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Changes in the action of morphine challenge following perinatal morphine exposure in rats Vaccination with different heat shock proteins (HSP60, HSP65) prevented the development of low-dose streptozotocin (STZ)-induced autoimmune diabetes in C57BL/KSJ mice. The aim of our work was to examine whether the vaccination with HSP65 can prevent the wellknown cardiac electrophysiological characteristics of diabetes. The electrophysiological effects of dofetilide (a class III antiarrhythmic drug) were also studied. Diabetes was induced by a low dose of STZ (3 × 30 mg/kg i.p.), the vaccination with HSP65 (100 μg/animal) occurred 7 days before STZ treatment. The parameters of transmembrane action potentials (APs) of right ventricular papillary muscles in rats were studied by the microelectrode technique. The previously observed prolongation of AP duration in diabetes induced by a high dose of STZ was recorded in the case of low dose of STZ too. The vaccination with HSP65 could not modify the increase of AP duration. Dofetilide (1-10 μM) did not cause any significant alterations in the parameters of AP either in diabetic or in the HSP-treated animals. Our results with dofetilide differ from published data. This result could be due to the fact that the ion current characteristic of the rat ventricular repolarization phase highly differs from that of other species. We need further experiments to find out additional explanations of our results. Certain drugs evidently exert their therapeutic effects via sodium channel inhibition: local anesthetics, class I antiarrhytmics and certain anticonvulsants. Novel sodium channel inhibitor compounds are actively investigated for other indications involving stroke, ischemia, various neurodegenerative conditions and pain syndroms. All these drugs cause voltage-and use-dependent inhibition of sodium channels. However, biophysical properties of inhibition can differ widely even between use-dependent sodium channel inhibitors which seem to act similarly.
Recently it has been proposed that the mechanism of inhibition can be more important than potency or isoform selectivity regarding the therapeutical potential of the drugs (e.g. [1] ). One important question is which conformational state is preferred by the drug. In this study we attempted to discriminate preference to fast-vs. slow-inactivated conformations. Slow association to fast-inactivated state and fast association to slow-inactivated state cannot be distinguished using traditional protocols. We have recently developed a protocol to test fast-vs. slow-inactivated state preference using electrophysiology only, i.e. without mutagenesis or enzymatic treatment experiments. We tested 28 use-dependent sodium channel inhibitors of different chemical structure and therapeutic indication using this protocol, and found that the mechanisms primarily overlap with the latter. 
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Exploring the heterogeneity of use-dependent sodium channel inhibitor drugs. II: Drugs described by the modulated receptor hypothesis (MRH) and/or the guarded receptor hypothesis (GRH) Arpad Mike, Nora Lenkey, Robert Karoly and E Sylvester Vizi Institute of Experimental Medicine, Budapest, Hungary E-Mail: mike@koki.hu
All therapeutically used sodium channel inhibitor drugs seem to act similarly: in a use-dependent and state-dependent manner. These properties, however, can be caused by multiple mechanisms, as we and others have previously
shown [1] . The two major hypotheses that explain use-and state-dependent inhibition are the MRH [2] and the GRH [3] . In this study we investigated which hypothesis better describes inhibition by various drugs, and whether drugs can be classified based on this aspect of their mechanism of action. We assumed that the two hypotheses are not mutually exclusive, and speculated that both altered affinity (as predicted by the MRH) and altered accessibility (as predicted by the GRH) to the inactivated state can be expressed as changes in association and dissociation rates upon conformational transition. We developed a method to test the relative contribution of affinity and accessibility in the effect of the drugs based on the degree of inhibition (reflecting affinity) and the time constant of the onset of inhibition (reflecting accessibility) as a function of changes in the voltage protocol. We tested the method by simulations and found that original parameters of a simulated drug can be deduced using the method. Experiments using 12 fastinactivated state-preferring use-dependent sodium channel inhibitors suggest significant differences in this aspect of the mechanism. 
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Electrophysiological characteristics of heart ventricular papillary muscles from histidine decarboxylase knockout and wild-type mice: effects of rosiglitazone Andrea Szebeni and Valéria Kecskeméti Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary E-Mail: szeband@pharma.sote.hu
Background:
Thiazolidinediones (troglitazone, rosiglitazone), synthetic peroxisome proliferator-activated receptor agonists, act as insulin sensitizers but beyond their antidiabetic actions improve cardiac function in experimental animals. Aim and Methods: Our first aim was to characterise the electrophysiological parameters of right ventricular papillary muscles from histidine decarboxylase knockout (HDC KO) mice compared with those of wild-type (WT) by standard microelectrode technique. Furthermore we investigated the effects of rosiglitazone (1, 3, 30 μM) on transmembrane action potentials. Results: In KO mice statistically significant prolongation of action potential duration (APD) and decrease in maximum rate of rise of depolarisation phase (V max , dV/dt) can be observed. Rosiglitazone caused a concentration-dependent shortening of APD in both types of mice but reduced V max only in WT mice.
Conclusions:
The most important difference in the electrophysiological parameters (APD, V max ) between HDC KO and WT mice could be due to the fact that HDC KO mice are more susceptible for hyperglycaemia. The results also suggest that rosiglitazone might act on K + channels and this effect might take part in the protective effect of rosiglitazone in ischemia/reperfusion injury observed in rats, but further, direct ionic current measurements need to support this explanation.
Morphine, the opioid analgesic most abundantly used for severe acute and chronic pain, is associated with several adverse effects such as respiratory depression, tolerance and dependence. The intensive search to find new opioids possessing a better pharmacological profile has resulted in 14-O-methyloxymorphone (14-O-MOX) and 14-methoxymetopon (MET), a highly µ-selective and very potent opioid agonist. Our aim was to test the compounds in the rat vas deferens (RVD) bioassay system in order to further analyze their µ receptor efficacy and elucidate the structure-activity relationship between the compounds and oxymorphone (OX), their parent molecule. RVD was prepared, mounted and stimulated as described by Ronai et al. [1] . Opioid actions were measured by determining the inhibitory effects on the electrically evoked twitches. Antagonist activity was determined by the single-dose method. MET exerted full agonist activity in RVD, unlike OX and 14-O-MOX which were only partial agonists. Naltrexone, the reference µ receptor antagonist, antagonized the inhibitory actions on the electrically evoked twitches of the test compounds with a similar potency than in mouse vas deferens indicating the presence of µ opioid receptors in RVD. We found that MET is a highly efficacious µ receptor agonist and that the 5-methyl substitution may be responsible for the full agonist activity. We could not prove the distinction between rat vas deferens and other µ receptor-containing organs. Introduction: Hyperinsulinaemia and insulin resistance are considered as independent risk factors of ischemic heart disease. We sought whether hyperinsulinaemia per se is of significant influence on cardiac arrhythmia generation in conscious rabbits. Methods: Chronically instrumented conscious rabbits were equipped with a right ventricular electrode catheter for pacing and recording the intracavitary electrogram as well as with arterial and venous catheters for blood sampling, blood pressure monitoring and for insulin and glucose infusions, respectively. Hyperinsulinaemia was produced by 2-step hyperinsulinaemic (35.7 ± 7.4 and 103.2 ± 10.5 µU/ml) euglycaemic (5.5 ± 0.5 µU/ml) glucose clamping. Programmed electrical stimulation (PES) was applied for ventricular effective refractory period (VERP) determination and arrhythmia generation.
Results:
The VERP shortened from 110.4 ± 3.7 to 104.8 ± 2.9 ms, (p < 0.05) and from 109.3 ± 2.9 to 101.4 ± 1.7 ms (p < 0.05) in animals with 35 and 103 µU/ml clamped hyperinsulinaemic euglycaemia, respectively. The incidence of ventricular premature beats, non-sustained ventricular tachycardia and sustained ventricular tachycardia induced by PES increased from control 11, 0, 0% to 24 (p < 0.05), 5, 0%; and 56, 44 (p < 0.001 for each), 0% in animals with 35 and 103 µU/ml clamped hyperinsulinaemic euglycaemia, respectively.
Conclusion:
The results provide evidence for the "sui generis" proarrhythmic effect of hyperinsulinaemia in otherwise healthy rabbits. The results also suggest that this is underpinned by a hyperinsulinaemia-induced reduction of VERP. Free radicals in biological systems play a major role in the onset of many diseases, e.g. oxygen-centered radicals such as hydroxyl or superoxide radicals. In order to identify and localize these radicals a series of four novel spin traps have been developed and their structure fully characterized by . Their spin trapping behaviour towards a series of different oxygen-and carbon-centered radicals is described. All compounds were obtained in two different stereochemical forms (cis and trans), but only 3,5-EEMPO and 5,3-EEMPO could be separated into the different diastereomers using conventional chromatographic procedures. The cis-and trans-forms exhibited considerably different spectral parameters and stabilities of the respective superoxide adducts (ranging from about 12 to 35 min). In addition, spin adducts obtained from different carbon-centered radicals derived from methanol, ethanol, formic acid and linoleic acid hydroperoxide have also been characterized. The aim of the present study was the establishment of an in vitro test system to reveal the potential risk to human health of nanoparticles at the workplace. The essential advantage of in vitro investigations is to be non-invasive, the employees don't have to be bothered and the work routine doesn't have to be intercepted. At occupational settings test cells on Transwell ® inserts were exposed to the workplace atmosphere or to particle filtered air for 1 to 3 hrs using a CULTEX ® System. 2 types of co-cultures were tested: In the first type differentiated macrophages were exposed and post-incubated with human lung epithelial cells. In the second type differentiated macrophages were seeded on human lung epithelial cells and the co-culture was exposed.
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As endpoints for particle exposure cell viability (WST-1 assay), oxidative stress (DHR-Assay) and pro-inflammatory cytokines (BDTM CBA-Assay) were evaluated. Cell viability testing showed a negative effect at high exposure. In cells exposed to the workplace atmosphere an increased oxidative burst was detected compared to cells exposed to particle filtered air. Exposure of co-cultures resulted in significantly enhanced TNF-α, IL-6, IL-1β and IL-8 levels.
We could show that our in vitro exposure system is very well adapted for the assessment of adverse effects of nanoparticles at the workplace. Our results indicate that nanoparticles involve an occupational risk and further experiments will be performed to analyse additional endpoints. 
